Physicochemical Properties
Molecular Formula | C20H21N3OS |
Molecular Weight | 351.47 |
CAS # | 2382959-65-9 |
SMILES | S(C1=NC2C=CC=CC=2N=C1C1C=CC=CC=1)CCC(=O)NCCC |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | Topoisomerase II 7.5 μM (IC50) |
ln Vitro | Topoisomerase II inhibitor 18 (0-100 μM) inhibits the proliferation of cancer cells PC-3 and HepG2 with IC50 values of 2.11 and 11.03 μM, respectively, and shows no significant cytotoxicity to normal Vero cells (IC50 is 23.12 μM)[1]. |
ln Vivo | Topoisomerase II inhibitor 18 (5 mg/kg, intramuscular injection for 21 days) has antitumor activity in the Ehrlich solid tumor model of albino mice and has renal protective effects [1]. |
Cell Assay |
Western Blot Analysis[1] Cell Types: PC-3 Tested Tested Concentrations: 0-100 μM Incubation Duration: 48 h Experimental Results: Increased levels of p53, cleaved caspase-3 and cleaved caspase-8. Decreased levels of Bcl-2. Cell Proliferation Assay[1] Cell Types: HepG2, PC-3 Tested Tested Concentrations: 0-100 μM Incubation Duration: 48 h Experimental Results: Inhibited proliferations of PC-3 and HepG2 |
Animal Protocol |
Animal/Disease Models: Ehrlich solid tumor bearing albino mice[1] Doses: 5 mg/kg Route of Administration: i.m. for 21 days Experimental Results: Inhibited tumor growth. |
References |
[1]. A quinoxaline-based derivative exhibited potent and selective anticancer activity with apoptosis induction in PC-3 cells through Topo II inhibition. J Biomol Struct Dyn. 2024 Mar 14:1-19. |
Solubility Data
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8452 mL | 14.2260 mL | 28.4519 mL | |
5 mM | 0.5690 mL | 2.8452 mL | 5.6904 mL | |
10 mM | 0.2845 mL | 1.4226 mL | 2.8452 mL |